SIRI was also important in unresectable stage III NSCLC patients treated with CRT (29) and advanced NSCLC patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (30). This evidence concerns the gene EGFR and non-small cell lung carcinoma.